These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12208340)

  • 21. The Application of Clinical Lithotripter Shock Waves to RNA Nucleotide Delivery to Cells.
    Nwokeoha S; Carlisle R; Cleveland RO
    Ultrasound Med Biol; 2016 Oct; 42(10):2478-92. PubMed ID: 27444864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma.
    Gao P; Ding Q; Wu Z; Jiang H; Fang Z
    Cancer Lett; 2010 Apr; 290(2):157-66. PubMed ID: 19786319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols.
    Favrot MC; Puisieux I
    Adv Exp Med Biol; 1998; 451():539-41. PubMed ID: 10026924
    [No Abstract]   [Full Text] [Related]  

  • 24. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
    J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
    Suh RD; Goldin JG; Wallace AB; Sheehan RE; Heinze SB; Gitlitz BJ; Figlin RA
    Radiology; 2004 May; 231(2):359-64. PubMed ID: 15128982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
    Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
    J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity.
    Hara S; Nagai H; Miyake H; Yamanaka K; Arakawa S; Ichihashi M; Kamidono S; Hara I
    J Urol; 2001 Jun; 165(6 Pt 1):2039-43. PubMed ID: 11371924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor efficacy and biodistribution of linear polyethylenimine-cholesterol/DNA complexes.
    Furgeson DY; Yockman JW; Janat MM; Kim SW
    Mol Ther; 2004 Jun; 9(6):837-45. PubMed ID: 15194050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.
    Nakanishi H; Mizutani Y; Kawauchi A; Ukimura O; Shiraishi T; Hatano M; Mizuno M; Yoshida J; Miki T
    Clin Cancer Res; 2003 Mar; 9(3):1129-35. PubMed ID: 12631618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma.
    Dybal EJ; Haas GP; Maughan RL; Sud S; Pontes JE; Hillman GG
    J Urol; 1992 Oct; 148(4):1331-7. PubMed ID: 1404669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
    Yockman JW; Kim WJ; Chang CW; Kim SW
    Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
    Schmidt-Wolf IG; Huhn D; Neubauer A; Wittig B
    Hum Gene Ther; 1994 Sep; 5(9):1161-8. PubMed ID: 7530496
    [No Abstract]   [Full Text] [Related]  

  • 37. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
    Marumo K; Oya M; Murai M; Tazaki H
    Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of radiotherapy by hyperthermia-regulated gene therapy.
    Lohr F; Hu K; Huang Q; Zhang L; Samulski TV; Dewhirst MW; Li CY
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1513-8. PubMed ID: 11121657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
    Kanwar JR; Shen WP; Kanwar RK; Berg RW; Krissansen GW
    J Natl Cancer Inst; 2001 Oct; 93(20):1541-52. PubMed ID: 11604477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.